At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses promising monoclonal antibodies in clinical development for the treatment of patients with multiple myeloma. Prof Lonial focuses on the basic and clinical aspects of several novel monoclonal antibodies, including daratumumab, which targets CD38, and elotuzumab, which targets signalling lymphocytic activation molecule-F7 (SLAMF7).
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement